Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone

• DOI: 10.1007/s00262-020-02594-9
• Publication Date: 2020-05-06T08:06:00Z
• Authors: Jasna Metovic; Laura Annaratone; Alessandra Linari; Simona Osella-Abate; Chiara Musuraca; Francesca Veneziano; Chiara Vignale; Luca Bertero; Paola Cassoni; Nicola Ratto; Alessandro Comandone; Giovanni Grignani; Raimondo Piana; Mauro Papotti
• Keywords: Immune checkpoint; Giant Cell Tumors; Univariate analysis

Giant cell tumor of bone (GCTB) is a locally aggressive and rarely metastatic tumor, with a relatively unpredictable clinical course. A retrospective series of 46 GCTB and a control group of 24 aneurysmal bone cysts (ABC) were selected with the aim of investigating the PD-L1 expression levels and immune-related gene expression profile, in correlation with clinicopathological features. PD-L1 and Ki67 were immunohistochemically tested in each case. Furthermore, comprehensive molecular analyses were carried out using NanoString technology and nCounter PanCancer Immune Profiling Panel, and the gene expression results were correlated with clinicopathological characteristics. PD-L1 expression was observed in 13/46 (28.3%) GCTB (and in 1/24, 4.2%, control ABC, only) and associated with a shorter disease free interval according to univariate analysis. Moreover, in PD-L1-positive lesions, three genes (CD27, CD6 and IL10) were significantly upregulated (p < 0.01), while two were downregulated (LCK and TLR8, showing borderline significance, p = 0.06). Interestingly, these genes can be related to maturation and immune tolerance of bone tissue microenvironment, suggesting a more immature/anergic phenotype of giant cell tumors. Our findings suggest that PD-L1 immunoreactivity may help to select GCTB patients with a higher risk of recurrence who could potentially benefit from immune checkpoint blockade.